Advanced prostate cancer patients who started androgen deprivation treatment (ADT) treatment with low testosterone levels had worse 1-year progression-free and overall survival after continuous ADT than men with higher testosterone levels. This means that men who are about to start hormone therapy should have their testosterone tested. Those with low testosterone levels should ask their [...]
Malecare and the University of Minnesota collaborated on the first study to investigate what gay and bisexual men are offered and what they try as rehabilitation to address the sexual and urinary effects of prostate cancer treatment. Gay and bisexual men with prostate cancer (N=193) from Malecare's online and in-person support groups completed survey questions asking [...]
The first whole slide imaging (WSI) system that allows for review and interpretation of digital prostate cancer pathology slides prepared from biopsied tissue has been approved by the U.S. Food and Drug Administration (FDA). Malecare is a leading advocate of second and third opinions of prostate cancer pathology from biopsy samples. The logistics of shipping and [...]
Adna is a new blood test that will tell you if Zytiga and Xtandi will or will not treat castration resistant prostate cancer. Imagine knowing if Zytiga and or Xtandi will fail to help you, before you spend months of time and thousands of dollars trying these drugs out. The test, called AdnaTest Prostate Cancer Panel [...]
An inherited genetic change, HSD3B1 gene causes Androgen Deprivation Therapy (ADT) to be less effective for treating metastatic prostate cancer. Physician-researcher Nima Sharifi, M.D. published this finding in the October, 2016 The Lancet Oncology. While Androgen Deprivation Therapy is effective for many men with advanced stage prostate cancer, prostate tumors eventually become resistant to ADT because the tumors make their own androgens. “A simple blood [...]